Liposomal Methylene Blue 12mg - World First

LIPOSOMAL METHYLENE BLUE 12MG

The Mitochondrial Electron Carrier. 100 Years of Clinical History. Finally Bio-optimised.

WHAT IS METHYLENE BLUE?

Methylene Blue (MB) is a phenothiazinium compound first synthesised in 1876. It was the first fully synthetic drug used in clinical medicine — initially for malaria treatment — and has since been approved by the FDA for methemoglobinaemia, cyanide poisoning, and ifosfamide-induced encephalopathy. It has one of the longest documented clinical safety records of any compound in pharmacological history. And yet, its most relevant biological activity for performance and longevity applications was not fully characterised until the last two decades: methylene blue is an alternative electron carrier in the mitochondrial electron transport chain.

MB exists in two redox states: the oxidised blue form (MB+) and the reduced colourless form (leucomethylene blue, MBH2). This redox cycling — MB+ accepting electrons and becoming MBH2, then donating electrons to Complex IV (cytochrome c oxidase) and returning to MB+ — allows MB to directly bypass damaged or dysfunctional Complex I, II, or III and shunt electrons directly to the terminal oxidase. In cells where upstream ETC dysfunction has impaired ATP production, MB restores electron flow and ATP synthesis through a completely different channel.

THE MOLECULAR MECHANISMS

Mitochondrial ETC Enhancement [T3–T4: cell and animal models]

In healthy mitochondria, MB increases the efficiency of Complex IV (cytochrome c oxidase), the terminal electron acceptor that reduces molecular oxygen to water. MB has a higher affinity for cytochrome c than Complex III does, meaning it can increase the rate of electron delivery to Complex IV even when upstream complexes are functioning normally. This translates to increased mitochondrial oxygen consumption and ATP production — effectively acting as a metabolic accelerator at the final step of oxidative phosphorylation. (Atamna et al., FASEB J, 2008)

Brain Ageing Research [T3–T4 preclinical; T1 derivative trials mixed]

Tau protein aggregation is a hallmark of age-related neurodegeneration, and MB has been studied for decades as a tau aggregation inhibitor. In cell and animal models, MB also reduces amyloid beta production, inhibits monoamine oxidase, and promotes autophagic clearance of misfolded proteins (Rojas et al., Prog Neurobiol, 2012). A second-generation MB derivative, LMTM, went through Phase III trials — the primary endpoints were not met (Gauthier et al., Lancet, 2016). This is research context on the compound, not a claim that this product treats, prevents, or cures any disease.

Cognition and Cerebral Blood Flow [T2: small human trials at higher doses]

MB crosses the blood-brain barrier rapidly and freely — a consequence of its small size (319 Da) and lipophilicity. In the brain, MB increases cytochrome c oxidase activity in neurons and improves cerebral blood flow via nitric oxide modulation. A human fMRI study found that a single ~280mg dose (~4mg/kg) increased task-related brain activity and improved short-term memory retrieval in healthy adults (Rodriguez et al., Radiology, 2016). That dose is substantially higher than 12mg — we cite it as mechanism evidence, not as an effect promised at this dose.

Antimicrobial and Anti-Biofilm Activity

Methylene blue is a photosensitiser — in the presence of visible light, it generates singlet oxygen and reactive oxygen species that are selectively toxic to microorganisms. This activity forms the basis of photodynamic therapy using MB for oral, wound, and sinus infections. It also has direct antimicrobial activity against certain intracellular pathogens (Plasmodium, Leishmania) independent of light activation.

DOSE, SAFETY, AND THE HORMETIC WINDOW

Methylene Blue demonstrates hormesis — a dose-response relationship where low doses have the opposite effect to high doses (Bruchey & Gonzalez-Lima, Eur J Pharmacol, 2008). Research describes low doses of roughly 0.5–4mg/kg (about 35–280mg for a 70kg adult) as the range where mitochondrial and neuroprotective effects are observed, while higher doses shift MB toward pro-oxidant activity and excessive monoamine oxidase inhibition.

Spawn Nutra Liposomal Methylene Blue at 12mg (about 0.17mg/kg for a 70kg adult) is deliberately conservative — it sits below the doses used in most human studies, well clear of the high-dose zone. The liposomal delivery system is how we aim to get more out of a low, defensible dose rather than chasing milligrams.

Contraindication note: MB is a monoamine oxidase inhibitor and should not be combined with SSRIs, SNRIs, MAOIs, or other serotonergic drugs (Ramsay et al., Br J Pharmacol, 2007). It is not appropriate for individuals with G6PD deficiency, or during pregnancy or breastfeeding. Speak to your doctor before use if you take any prescription medication.

THE LIPOSOMAL ADVANTAGE

MAD SCIENTIST 5150 — FORMULATE TO DESTROY

A drug older than aspirin, with a century of clinical history and a mitochondrial mechanism most nootropics can only dream about. Spawn Nutra Liposomal Methylene Blue 12mg — low dose, liposomal delivery, no hype. This is what the horizon looks like.